

HRES 280

Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Foreign Trade and International Finance

Introduced: Mar 26, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 29, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-resolution/280>

Sponsor

Name: Rep. Jackson, Ronny [R-TX-13]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (14 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Baird, James R. [R-IN-4]	R · IN		Mar 26, 2021
Rep. Banks, Jim [R-IN-3]	R · IN		Mar 26, 2021
Rep. Franklin, C. Scott [R-FL-15]	R · FL		Mar 26, 2021
Rep. Herrell, Yvette [R-NM-2]	R · NM		Mar 26, 2021
Rep. Hice, Jody B. [R-GA-10]	R · GA		Mar 26, 2021
Rep. Mast, Brian J. [R-FL-18]	R · FL		Mar 26, 2021
Rep. McClintock, Tom [R-CA-4]	R · CA		Mar 26, 2021
Rep. Roy, Chip [R-TX-21]	R · TX		Mar 26, 2021
Rep. Salazar, Maria Elvira [R-FL-27]	R · FL		Mar 26, 2021
Rep. Tenney, Claudia [R-NY-22]	R · NY		Mar 26, 2021
Rep. Harshbarger, Diana [R-TN-11]	R · TN		Apr 1, 2021
Rep. Carter, John R. [R-TX-31]	R · TX		Apr 13, 2021
Rep. Rutherford, John H. [R-FL-4]	R · FL		Apr 13, 2021
Rep. Spartz, Victoria [R-IN-5]	R · IN		Jun 8, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 29, 2021
Foreign Affairs Committee	House	Referred To	Mar 26, 2021
Ways and Means Committee	House	Referred to	Mar 26, 2021

Subjects & Policy Tags

Policy Area:

Foreign Trade and International Finance

Related Bills

No related bills are listed.

Summary (as of Mar 26, 2021)

This resolution commits to the use of competitive free market and free trade policies to combat national security threats caused by China and its attacks on the U.S. pharmaceutical manufacturing base.

The resolution urges the United States to (1) remove tax, regulatory, and debt burdens and barriers that have weakened this base; (2) empower the U.S. Trade Representative to take specified actions to counter harmful and unfair trade practices by China; (3) address shortcomings in Food and Drug Administration data collection related to foreign-sourced pharmaceutical ingredients; and (4) identify and streamline regulatory hurdles that have impeded the U.S. pharmaceutical manufacturing base.

Actions Timeline

- **Mar 29, 2021:** Referred to the Subcommittee on Health.
- **Mar 26, 2021:** Introduced in House
- **Mar 26, 2021:** Referred to the Subcommittee on Trade.
- **Mar 26, 2021:** Referred to the Committee on Ways and Means, and in addition to the Committees on Foreign Affairs, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.